Browse the evidence

Targeted antiobesity medications (AOM) have demonstrated significant weight loss and improved quality of life in patients with specific genetic obesity disorders.

Practitioners should consider targeted AOMs for patients with genetic obesity disorders to improve weight management and quality of life.

Nontargeted AOMs can achieve similar benefits in patients with specific genetic obesity disorders compared to common multifactorial obesity.

Practitioners may consider nontargeted AOMs as an alternative for managing obesity in patients with genetic disorders.

GLP-1RA-induced weight loss would lead to a marked decrease in cancer cases over 10 years in adults.

Implementing GLP-1RA treatments could significantly reduce cancer incidence in obese populations.

If GLP-1RAs were made available for all people with obesity and 50% moved into a lower BMI category, there would be a simulated reduction in cumulative cancer cases of 21,443.

Wider access to GLP-1RAs could lead to significant reductions in cancer cases among obese individuals.

Significant reductions in diastolic BP (-1.5 mm Hg) and systolic BP (-1.1 mm Hg) were observed.

Semaglutide may help lower blood pressure in adults.

GLP-1 receptor agonists promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.

GLP-1 receptor agonists can be considered for managing type 2 diabetes and obesity in clinical practice.

GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes.

Consider GLP-1 receptor agonists for patients at high risk of cardiovascular issues or renal failure.

The preoperative weight loss intervention was feasible and viewed favorably among patients, with 83% feeling that video calls were helpful.

Practitioners can consider using video consultations as a supportive tool for weight loss interventions.

The unique combination of naltrexone and bupropion in NB-ER may work together to target POMC cells to prevent endogenous negative feedback, thereby decreasing appetite.

Understanding the mechanism can help practitioners explain the treatment's effects to patients.

Metabolic adaptation hinders the efficacy of obesity management strategies.

Understanding metabolic adaptation can help practitioners develop more effective obesity management strategies.

Bariatric surgery is a highly effective intervention to induce weight loss with durability over 10 or more years.

Bariatric surgery can be considered a long-term solution for significant weight loss.

Tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.

Tirzepatide may be a promising treatment option for patients with MASH, potentially improving liver health.

More patients in the tirzepatide group achieved a 1-stage or greater fibrosis improvement without worsening of MASH compared to placebo.

Tirzepatide may help improve liver fibrosis in patients with MASH.

Tirzepatide has been approved for the treatment of adults with type 2 diabetes who are overweight/obese or have weight-related comorbidities.

Tirzepatide is a viable treatment option for managing type 2 diabetes in specific patient populations.

Innovative solutions are needed to implement sustainable lifestyle modification interventions for T2D.

Practitioners should advocate for and develop innovative strategies to enhance lifestyle intervention adherence.

There is a distinct correlation between type 2 diabetes status and the likelihood of heart failure.

Recognizing this correlation can guide healthcare providers in monitoring and managing heart health in diabetic patients.

GLP-1 receptor agonists have demonstrated cardioprotection in patients with type 2 diabetes and heart failure.

Incorporating GLP-1RAs into treatment plans may improve cardiovascular outcomes in diabetic patients.

Weight gain within the first 6 months was associated with increased risk of HbA1c >7.5% and subsequent cardiovascular disease (CVD) with a hazard ratio (HR) of 1.03.

Clinicians should monitor weight changes in T2D patients as it may impact glycemic control and cardiovascular health.

Weight gain at 1 year was associated with increased risk of HbA1c >7.5% (HR 1.05) and kidney disease (HR 1.03).

Weight management is crucial for T2D patients to prevent worsening glycemic control and kidney disease.

Weight gain was associated with lower diabetes treatment satisfaction.

Healthcare providers should address weight management to improve patient satisfaction with diabetes treatment.

Obesity increases the risk of postoperative complications following elective surgery.

Surgeons should consider obesity as a significant risk factor when planning surgeries.

An interdisciplinary approach is necessary for effective weight loss treatment in obese patients before joint replacement surgery.

Healthcare teams should collaborate across disciplines to optimize weight loss strategies for these patients.

Soy isoflavones may be helpful in treating conditions such as insulin resistance, inflammation, cardiovascular disease, and intestinal dysbiosis.

Soy isoflavones could be considered as a potential treatment option for various metabolic conditions associated with PCOS.

CRDs improved hepatic stress (GGT: SMD = -6.08 U/L) and renal function (UACR: SMD = -0.19).

CRDs may be beneficial for improving liver and kidney health in adults.